Global Etanercept Market
Global Etanercept Market

Etanercept Comprehensive Study by Type (Enbrel, Benepali), Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA), Others) Players and Region - Global Market Outlook to 2024

Etanercept Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Dec 2019 Edition 235 Pages 222 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Etanercept is a tumor necrosis factor antagonist that is used for the treatment of adult and juvenile from rheumatoid arthritis, it is also known as biopharmaceutical which is also used to treat autoimmune disorders. This biopharmaceutical is the United States FDA approved to treat psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis and many more diseases. Hence, rising accidents and obesity is growing in the industry.

Market Drivers
  • Increasing Prevalence of Rising Diseases such as Obesity and Accidents
  • Rising Awareness about the Diseases such as Arthritis is also Driving the Market


Restraints
  • Growing Government Regulation Associated with Saftey and Efficiency of Etanercept can Hamper the market

Opportunities
Growing Healthcare Expenditure and Government Support is Boosting the Industry

Players Covered in the Study are:
Amgen (United States), Pfizer (United States), Takeda (Japan), Sanofi (France), GlaxoSmithKline (United Kingdom), Sandoz (Germany), Celltrion (South Korea), Dexa Medica (Indonesia), Bionovis (Brazil) and Momenta Pharmaceuticals (United States)

The Global Etanercept market is gaining huge competition due to involvement of Global companies that constantly invest in research & development to meet market expectation with new innovation.

Available Customization:
List of players that can be included in the study on immediate basis are HanAll Biopharma (South Korea), MedImmune (United States) and Tsumura (Japan).

Report Objectives / Segmentation Covered
By Type
  • Enbrel
  • Benepali
By Application
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Juvenile idiopathic arthritis (JIA)
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Rising Diseases such as Obesity and Accidents
      • 3.2.2. Rising Awareness about the Diseases such as Arthritis is also Driving the Market
    • 3.3. Market Challenges
      • 3.3.1. Issue Related Towards the Side Effects of this Etanercept such as Lower Ability of Immune System, Heart failure and Many More
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Etanercept, by Type, Application and Region (value, volume and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Etanercept (Value)
      • 5.2.1. Global Etanercept by: Type (Value)
        • 5.2.1.1. Enbrel
        • 5.2.1.2. Benepali
      • 5.2.2. Global Etanercept by: Application (Value)
        • 5.2.2.1. Rheumatoid arthritis
        • 5.2.2.2. Psoriatic arthritis
        • 5.2.2.3. Ankylosing spondylitis
        • 5.2.2.4. Juvenile idiopathic arthritis (JIA)
        • 5.2.2.5. Others
      • 5.2.3. Global Etanercept Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Etanercept (Volume)
      • 5.3.1. Global Etanercept by: Type (Volume)
        • 5.3.1.1. Enbrel
        • 5.3.1.2. Benepali
      • 5.3.2. Global Etanercept by: Application (Volume)
        • 5.3.2.1. Rheumatoid arthritis
        • 5.3.2.2. Psoriatic arthritis
        • 5.3.2.3. Ankylosing spondylitis
        • 5.3.2.4. Juvenile idiopathic arthritis (JIA)
        • 5.3.2.5. Others
      • 5.3.3. Global Etanercept Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Etanercept (Price)
      • 5.4.1. Global Etanercept by: Type (Price)
  • 6. Etanercept: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Celltrion (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Dexa Medica (Indonesia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bionovis (Brazil)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Momenta Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Etanercept Sale, by Type, Application and Region (value, volume and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Etanercept (Value)
      • 7.2.1. Global Etanercept by: Type (Value)
        • 7.2.1.1. Enbrel
        • 7.2.1.2. Benepali
      • 7.2.2. Global Etanercept by: Application (Value)
        • 7.2.2.1. Rheumatoid arthritis
        • 7.2.2.2. Psoriatic arthritis
        • 7.2.2.3. Ankylosing spondylitis
        • 7.2.2.4. Juvenile idiopathic arthritis (JIA)
        • 7.2.2.5. Others
      • 7.2.3. Global Etanercept Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Etanercept (Volume)
      • 7.3.1. Global Etanercept by: Type (Volume)
        • 7.3.1.1. Enbrel
        • 7.3.1.2. Benepali
      • 7.3.2. Global Etanercept by: Application (Volume)
        • 7.3.2.1. Rheumatoid arthritis
        • 7.3.2.2. Psoriatic arthritis
        • 7.3.2.3. Ankylosing spondylitis
        • 7.3.2.4. Juvenile idiopathic arthritis (JIA)
        • 7.3.2.5. Others
      • 7.3.3. Global Etanercept Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Etanercept (Price)
      • 7.4.1. Global Etanercept by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Etanercept: by Type(USD Million)
  • Table 2. Etanercept Enbrel , by Region USD Million (2013-2018)
  • Table 3. Etanercept Benepali , by Region USD Million (2013-2018)
  • Table 4. Etanercept: by Application(USD Million)
  • Table 5. Etanercept Rheumatoid arthritis , by Region USD Million (2013-2018)
  • Table 6. Etanercept Psoriatic arthritis , by Region USD Million (2013-2018)
  • Table 7. Etanercept Ankylosing spondylitis , by Region USD Million (2013-2018)
  • Table 8. Etanercept Juvenile idiopathic arthritis (JIA) , by Region USD Million (2013-2018)
  • Table 9. Etanercept Others , by Region USD Million (2013-2018)
  • Table 10. South America Etanercept, by Country USD Million (2013-2018)
  • Table 11. South America Etanercept, by Type USD Million (2013-2018)
  • Table 12. South America Etanercept, by Application USD Million (2013-2018)
  • Table 13. Brazil Etanercept, by Type USD Million (2013-2018)
  • Table 14. Brazil Etanercept, by Application USD Million (2013-2018)
  • Table 15. Argentina Etanercept, by Type USD Million (2013-2018)
  • Table 16. Argentina Etanercept, by Application USD Million (2013-2018)
  • Table 17. Rest of South America Etanercept, by Type USD Million (2013-2018)
  • Table 18. Rest of South America Etanercept, by Application USD Million (2013-2018)
  • Table 19. Asia Pacific Etanercept, by Country USD Million (2013-2018)
  • Table 20. Asia Pacific Etanercept, by Type USD Million (2013-2018)
  • Table 21. Asia Pacific Etanercept, by Application USD Million (2013-2018)
  • Table 22. China Etanercept, by Type USD Million (2013-2018)
  • Table 23. China Etanercept, by Application USD Million (2013-2018)
  • Table 24. Japan Etanercept, by Type USD Million (2013-2018)
  • Table 25. Japan Etanercept, by Application USD Million (2013-2018)
  • Table 26. India Etanercept, by Type USD Million (2013-2018)
  • Table 27. India Etanercept, by Application USD Million (2013-2018)
  • Table 28. South Korea Etanercept, by Type USD Million (2013-2018)
  • Table 29. South Korea Etanercept, by Application USD Million (2013-2018)
  • Table 30. Taiwan Etanercept, by Type USD Million (2013-2018)
  • Table 31. Taiwan Etanercept, by Application USD Million (2013-2018)
  • Table 32. Australia Etanercept, by Type USD Million (2013-2018)
  • Table 33. Australia Etanercept, by Application USD Million (2013-2018)
  • Table 34. Rest of Asia-Pacific Etanercept, by Type USD Million (2013-2018)
  • Table 35. Rest of Asia-Pacific Etanercept, by Application USD Million (2013-2018)
  • Table 36. Europe Etanercept, by Country USD Million (2013-2018)
  • Table 37. Europe Etanercept, by Type USD Million (2013-2018)
  • Table 38. Europe Etanercept, by Application USD Million (2013-2018)
  • Table 39. Germany Etanercept, by Type USD Million (2013-2018)
  • Table 40. Germany Etanercept, by Application USD Million (2013-2018)
  • Table 41. France Etanercept, by Type USD Million (2013-2018)
  • Table 42. France Etanercept, by Application USD Million (2013-2018)
  • Table 43. Italy Etanercept, by Type USD Million (2013-2018)
  • Table 44. Italy Etanercept, by Application USD Million (2013-2018)
  • Table 45. United Kingdom Etanercept, by Type USD Million (2013-2018)
  • Table 46. United Kingdom Etanercept, by Application USD Million (2013-2018)
  • Table 47. Netherlands Etanercept, by Type USD Million (2013-2018)
  • Table 48. Netherlands Etanercept, by Application USD Million (2013-2018)
  • Table 49. Rest of Europe Etanercept, by Type USD Million (2013-2018)
  • Table 50. Rest of Europe Etanercept, by Application USD Million (2013-2018)
  • Table 51. MEA Etanercept, by Country USD Million (2013-2018)
  • Table 52. MEA Etanercept, by Type USD Million (2013-2018)
  • Table 53. MEA Etanercept, by Application USD Million (2013-2018)
  • Table 54. Middle East Etanercept, by Type USD Million (2013-2018)
  • Table 55. Middle East Etanercept, by Application USD Million (2013-2018)
  • Table 56. Africa Etanercept, by Type USD Million (2013-2018)
  • Table 57. Africa Etanercept, by Application USD Million (2013-2018)
  • Table 58. North America Etanercept, by Country USD Million (2013-2018)
  • Table 59. North America Etanercept, by Type USD Million (2013-2018)
  • Table 60. North America Etanercept, by Application USD Million (2013-2018)
  • Table 61. United States Etanercept, by Type USD Million (2013-2018)
  • Table 62. United States Etanercept, by Application USD Million (2013-2018)
  • Table 63. Canada Etanercept, by Type USD Million (2013-2018)
  • Table 64. Canada Etanercept, by Application USD Million (2013-2018)
  • Table 65. Mexico Etanercept, by Type USD Million (2013-2018)
  • Table 66. Mexico Etanercept, by Application USD Million (2013-2018)
  • Table 67. Etanercept Sales: by Type(Unit)
  • Table 68. Etanercept Sales Enbrel , by Region Unit (2013-2018)
  • Table 69. Etanercept Sales Benepali , by Region Unit (2013-2018)
  • Table 70. Etanercept Sales: by Application(Unit)
  • Table 71. Etanercept Sales Rheumatoid arthritis , by Region Unit (2013-2018)
  • Table 72. Etanercept Sales Psoriatic arthritis , by Region Unit (2013-2018)
  • Table 73. Etanercept Sales Ankylosing spondylitis , by Region Unit (2013-2018)
  • Table 74. Etanercept Sales Juvenile idiopathic arthritis (JIA) , by Region Unit (2013-2018)
  • Table 75. Etanercept Sales Others , by Region Unit (2013-2018)
  • Table 76. South America Etanercept Sales, by Country Unit (2013-2018)
  • Table 77. South America Etanercept Sales, by Type Unit (2013-2018)
  • Table 78. South America Etanercept Sales, by Application Unit (2013-2018)
  • Table 79. Brazil Etanercept Sales, by Type Unit (2013-2018)
  • Table 80. Brazil Etanercept Sales, by Application Unit (2013-2018)
  • Table 81. Argentina Etanercept Sales, by Type Unit (2013-2018)
  • Table 82. Argentina Etanercept Sales, by Application Unit (2013-2018)
  • Table 83. Rest of South America Etanercept Sales, by Type Unit (2013-2018)
  • Table 84. Rest of South America Etanercept Sales, by Application Unit (2013-2018)
  • Table 85. Asia Pacific Etanercept Sales, by Country Unit (2013-2018)
  • Table 86. Asia Pacific Etanercept Sales, by Type Unit (2013-2018)
  • Table 87. Asia Pacific Etanercept Sales, by Application Unit (2013-2018)
  • Table 88. China Etanercept Sales, by Type Unit (2013-2018)
  • Table 89. China Etanercept Sales, by Application Unit (2013-2018)
  • Table 90. Japan Etanercept Sales, by Type Unit (2013-2018)
  • Table 91. Japan Etanercept Sales, by Application Unit (2013-2018)
  • Table 92. India Etanercept Sales, by Type Unit (2013-2018)
  • Table 93. India Etanercept Sales, by Application Unit (2013-2018)
  • Table 94. South Korea Etanercept Sales, by Type Unit (2013-2018)
  • Table 95. South Korea Etanercept Sales, by Application Unit (2013-2018)
  • Table 96. Taiwan Etanercept Sales, by Type Unit (2013-2018)
  • Table 97. Taiwan Etanercept Sales, by Application Unit (2013-2018)
  • Table 98. Australia Etanercept Sales, by Type Unit (2013-2018)
  • Table 99. Australia Etanercept Sales, by Application Unit (2013-2018)
  • Table 100. Rest of Asia-Pacific Etanercept Sales, by Type Unit (2013-2018)
  • Table 101. Rest of Asia-Pacific Etanercept Sales, by Application Unit (2013-2018)
  • Table 102. Europe Etanercept Sales, by Country Unit (2013-2018)
  • Table 103. Europe Etanercept Sales, by Type Unit (2013-2018)
  • Table 104. Europe Etanercept Sales, by Application Unit (2013-2018)
  • Table 105. Germany Etanercept Sales, by Type Unit (2013-2018)
  • Table 106. Germany Etanercept Sales, by Application Unit (2013-2018)
  • Table 107. France Etanercept Sales, by Type Unit (2013-2018)
  • Table 108. France Etanercept Sales, by Application Unit (2013-2018)
  • Table 109. Italy Etanercept Sales, by Type Unit (2013-2018)
  • Table 110. Italy Etanercept Sales, by Application Unit (2013-2018)
  • Table 111. United Kingdom Etanercept Sales, by Type Unit (2013-2018)
  • Table 112. United Kingdom Etanercept Sales, by Application Unit (2013-2018)
  • Table 113. Netherlands Etanercept Sales, by Type Unit (2013-2018)
  • Table 114. Netherlands Etanercept Sales, by Application Unit (2013-2018)
  • Table 115. Rest of Europe Etanercept Sales, by Type Unit (2013-2018)
  • Table 116. Rest of Europe Etanercept Sales, by Application Unit (2013-2018)
  • Table 117. MEA Etanercept Sales, by Country Unit (2013-2018)
  • Table 118. MEA Etanercept Sales, by Type Unit (2013-2018)
  • Table 119. MEA Etanercept Sales, by Application Unit (2013-2018)
  • Table 120. Middle East Etanercept Sales, by Type Unit (2013-2018)
  • Table 121. Middle East Etanercept Sales, by Application Unit (2013-2018)
  • Table 122. Africa Etanercept Sales, by Type Unit (2013-2018)
  • Table 123. Africa Etanercept Sales, by Application Unit (2013-2018)
  • Table 124. North America Etanercept Sales, by Country Unit (2013-2018)
  • Table 125. North America Etanercept Sales, by Type Unit (2013-2018)
  • Table 126. North America Etanercept Sales, by Application Unit (2013-2018)
  • Table 127. United States Etanercept Sales, by Type Unit (2013-2018)
  • Table 128. United States Etanercept Sales, by Application Unit (2013-2018)
  • Table 129. Canada Etanercept Sales, by Type Unit (2013-2018)
  • Table 130. Canada Etanercept Sales, by Application Unit (2013-2018)
  • Table 131. Mexico Etanercept Sales, by Type Unit (2013-2018)
  • Table 132. Mexico Etanercept Sales, by Application Unit (2013-2018)
  • Table 133. Etanercept: by Type(USD/Units)
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Etanercept: by Type(USD Million)
  • Table 145. Etanercept Enbrel , by Region USD Million (2019-2024)
  • Table 146. Etanercept Benepali , by Region USD Million (2019-2024)
  • Table 147. Etanercept: by Application(USD Million)
  • Table 148. Etanercept Rheumatoid arthritis , by Region USD Million (2019-2024)
  • Table 149. Etanercept Psoriatic arthritis , by Region USD Million (2019-2024)
  • Table 150. Etanercept Ankylosing spondylitis , by Region USD Million (2019-2024)
  • Table 151. Etanercept Juvenile idiopathic arthritis (JIA) , by Region USD Million (2019-2024)
  • Table 152. Etanercept Others , by Region USD Million (2019-2024)
  • Table 153. South America Etanercept, by Country USD Million (2019-2024)
  • Table 154. South America Etanercept, by Type USD Million (2019-2024)
  • Table 155. South America Etanercept, by Application USD Million (2019-2024)
  • Table 156. Brazil Etanercept, by Type USD Million (2019-2024)
  • Table 157. Brazil Etanercept, by Application USD Million (2019-2024)
  • Table 158. Argentina Etanercept, by Type USD Million (2019-2024)
  • Table 159. Argentina Etanercept, by Application USD Million (2019-2024)
  • Table 160. Rest of South America Etanercept, by Type USD Million (2019-2024)
  • Table 161. Rest of South America Etanercept, by Application USD Million (2019-2024)
  • Table 162. Asia Pacific Etanercept, by Country USD Million (2019-2024)
  • Table 163. Asia Pacific Etanercept, by Type USD Million (2019-2024)
  • Table 164. Asia Pacific Etanercept, by Application USD Million (2019-2024)
  • Table 165. China Etanercept, by Type USD Million (2019-2024)
  • Table 166. China Etanercept, by Application USD Million (2019-2024)
  • Table 167. Japan Etanercept, by Type USD Million (2019-2024)
  • Table 168. Japan Etanercept, by Application USD Million (2019-2024)
  • Table 169. India Etanercept, by Type USD Million (2019-2024)
  • Table 170. India Etanercept, by Application USD Million (2019-2024)
  • Table 171. South Korea Etanercept, by Type USD Million (2019-2024)
  • Table 172. South Korea Etanercept, by Application USD Million (2019-2024)
  • Table 173. Taiwan Etanercept, by Type USD Million (2019-2024)
  • Table 174. Taiwan Etanercept, by Application USD Million (2019-2024)
  • Table 175. Australia Etanercept, by Type USD Million (2019-2024)
  • Table 176. Australia Etanercept, by Application USD Million (2019-2024)
  • Table 177. Rest of Asia-Pacific Etanercept, by Type USD Million (2019-2024)
  • Table 178. Rest of Asia-Pacific Etanercept, by Application USD Million (2019-2024)
  • Table 179. Europe Etanercept, by Country USD Million (2019-2024)
  • Table 180. Europe Etanercept, by Type USD Million (2019-2024)
  • Table 181. Europe Etanercept, by Application USD Million (2019-2024)
  • Table 182. Germany Etanercept, by Type USD Million (2019-2024)
  • Table 183. Germany Etanercept, by Application USD Million (2019-2024)
  • Table 184. France Etanercept, by Type USD Million (2019-2024)
  • Table 185. France Etanercept, by Application USD Million (2019-2024)
  • Table 186. Italy Etanercept, by Type USD Million (2019-2024)
  • Table 187. Italy Etanercept, by Application USD Million (2019-2024)
  • Table 188. United Kingdom Etanercept, by Type USD Million (2019-2024)
  • Table 189. United Kingdom Etanercept, by Application USD Million (2019-2024)
  • Table 190. Netherlands Etanercept, by Type USD Million (2019-2024)
  • Table 191. Netherlands Etanercept, by Application USD Million (2019-2024)
  • Table 192. Rest of Europe Etanercept, by Type USD Million (2019-2024)
  • Table 193. Rest of Europe Etanercept, by Application USD Million (2019-2024)
  • Table 194. MEA Etanercept, by Country USD Million (2019-2024)
  • Table 195. MEA Etanercept, by Type USD Million (2019-2024)
  • Table 196. MEA Etanercept, by Application USD Million (2019-2024)
  • Table 197. Middle East Etanercept, by Type USD Million (2019-2024)
  • Table 198. Middle East Etanercept, by Application USD Million (2019-2024)
  • Table 199. Africa Etanercept, by Type USD Million (2019-2024)
  • Table 200. Africa Etanercept, by Application USD Million (2019-2024)
  • Table 201. North America Etanercept, by Country USD Million (2019-2024)
  • Table 202. North America Etanercept, by Type USD Million (2019-2024)
  • Table 203. North America Etanercept, by Application USD Million (2019-2024)
  • Table 204. United States Etanercept, by Type USD Million (2019-2024)
  • Table 205. United States Etanercept, by Application USD Million (2019-2024)
  • Table 206. Canada Etanercept, by Type USD Million (2019-2024)
  • Table 207. Canada Etanercept, by Application USD Million (2019-2024)
  • Table 208. Mexico Etanercept, by Type USD Million (2019-2024)
  • Table 209. Mexico Etanercept, by Application USD Million (2019-2024)
  • Table 210. Etanercept Sales: by Type(Unit)
  • Table 211. Etanercept Sales Enbrel , by Region Unit (2019-2024)
  • Table 212. Etanercept Sales Benepali , by Region Unit (2019-2024)
  • Table 213. Etanercept Sales: by Application(Unit)
  • Table 214. Etanercept Sales Rheumatoid arthritis , by Region Unit (2019-2024)
  • Table 215. Etanercept Sales Psoriatic arthritis , by Region Unit (2019-2024)
  • Table 216. Etanercept Sales Ankylosing spondylitis , by Region Unit (2019-2024)
  • Table 217. Etanercept Sales Juvenile idiopathic arthritis (JIA) , by Region Unit (2019-2024)
  • Table 218. Etanercept Sales Others , by Region Unit (2019-2024)
  • Table 219. South America Etanercept Sales, by Country Unit (2019-2024)
  • Table 220. South America Etanercept Sales, by Type Unit (2019-2024)
  • Table 221. South America Etanercept Sales, by Application Unit (2019-2024)
  • Table 222. Brazil Etanercept Sales, by Type Unit (2019-2024)
  • Table 223. Brazil Etanercept Sales, by Application Unit (2019-2024)
  • Table 224. Argentina Etanercept Sales, by Type Unit (2019-2024)
  • Table 225. Argentina Etanercept Sales, by Application Unit (2019-2024)
  • Table 226. Rest of South America Etanercept Sales, by Type Unit (2019-2024)
  • Table 227. Rest of South America Etanercept Sales, by Application Unit (2019-2024)
  • Table 228. Asia Pacific Etanercept Sales, by Country Unit (2019-2024)
  • Table 229. Asia Pacific Etanercept Sales, by Type Unit (2019-2024)
  • Table 230. Asia Pacific Etanercept Sales, by Application Unit (2019-2024)
  • Table 231. China Etanercept Sales, by Type Unit (2019-2024)
  • Table 232. China Etanercept Sales, by Application Unit (2019-2024)
  • Table 233. Japan Etanercept Sales, by Type Unit (2019-2024)
  • Table 234. Japan Etanercept Sales, by Application Unit (2019-2024)
  • Table 235. India Etanercept Sales, by Type Unit (2019-2024)
  • Table 236. India Etanercept Sales, by Application Unit (2019-2024)
  • Table 237. South Korea Etanercept Sales, by Type Unit (2019-2024)
  • Table 238. South Korea Etanercept Sales, by Application Unit (2019-2024)
  • Table 239. Taiwan Etanercept Sales, by Type Unit (2019-2024)
  • Table 240. Taiwan Etanercept Sales, by Application Unit (2019-2024)
  • Table 241. Australia Etanercept Sales, by Type Unit (2019-2024)
  • Table 242. Australia Etanercept Sales, by Application Unit (2019-2024)
  • Table 243. Rest of Asia-Pacific Etanercept Sales, by Type Unit (2019-2024)
  • Table 244. Rest of Asia-Pacific Etanercept Sales, by Application Unit (2019-2024)
  • Table 245. Europe Etanercept Sales, by Country Unit (2019-2024)
  • Table 246. Europe Etanercept Sales, by Type Unit (2019-2024)
  • Table 247. Europe Etanercept Sales, by Application Unit (2019-2024)
  • Table 248. Germany Etanercept Sales, by Type Unit (2019-2024)
  • Table 249. Germany Etanercept Sales, by Application Unit (2019-2024)
  • Table 250. France Etanercept Sales, by Type Unit (2019-2024)
  • Table 251. France Etanercept Sales, by Application Unit (2019-2024)
  • Table 252. Italy Etanercept Sales, by Type Unit (2019-2024)
  • Table 253. Italy Etanercept Sales, by Application Unit (2019-2024)
  • Table 254. United Kingdom Etanercept Sales, by Type Unit (2019-2024)
  • Table 255. United Kingdom Etanercept Sales, by Application Unit (2019-2024)
  • Table 256. Netherlands Etanercept Sales, by Type Unit (2019-2024)
  • Table 257. Netherlands Etanercept Sales, by Application Unit (2019-2024)
  • Table 258. Rest of Europe Etanercept Sales, by Type Unit (2019-2024)
  • Table 259. Rest of Europe Etanercept Sales, by Application Unit (2019-2024)
  • Table 260. MEA Etanercept Sales, by Country Unit (2019-2024)
  • Table 261. MEA Etanercept Sales, by Type Unit (2019-2024)
  • Table 262. MEA Etanercept Sales, by Application Unit (2019-2024)
  • Table 263. Middle East Etanercept Sales, by Type Unit (2019-2024)
  • Table 264. Middle East Etanercept Sales, by Application Unit (2019-2024)
  • Table 265. Africa Etanercept Sales, by Type Unit (2019-2024)
  • Table 266. Africa Etanercept Sales, by Application Unit (2019-2024)
  • Table 267. North America Etanercept Sales, by Country Unit (2019-2024)
  • Table 268. North America Etanercept Sales, by Type Unit (2019-2024)
  • Table 269. North America Etanercept Sales, by Application Unit (2019-2024)
  • Table 270. United States Etanercept Sales, by Type Unit (2019-2024)
  • Table 271. United States Etanercept Sales, by Application Unit (2019-2024)
  • Table 272. Canada Etanercept Sales, by Type Unit (2019-2024)
  • Table 273. Canada Etanercept Sales, by Application Unit (2019-2024)
  • Table 274. Mexico Etanercept Sales, by Type Unit (2019-2024)
  • Table 275. Mexico Etanercept Sales, by Application Unit (2019-2024)
  • Table 276. Etanercept: by Type(USD/Units)
  • Table 277. Research Programs/Design for This Report
  • Table 278. Key Data Information from Secondary Sources
  • Table 279. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Etanercept: by Type USD Million (2013-2018)
  • Figure 5. Global Etanercept: by Application USD Million (2013-2018)
  • Figure 6. South America Etanercept Share (%), by Country
  • Figure 7. Asia Pacific Etanercept Share (%), by Country
  • Figure 8. Europe Etanercept Share (%), by Country
  • Figure 9. MEA Etanercept Share (%), by Country
  • Figure 10. North America Etanercept Share (%), by Country
  • Figure 11. Global Etanercept: by Type Unit (2013-2018)
  • Figure 12. Global Etanercept: by Application Unit (2013-2018)
  • Figure 13. South America Etanercept Share (%), by Country
  • Figure 14. Asia Pacific Etanercept Share (%), by Country
  • Figure 15. Europe Etanercept Share (%), by Country
  • Figure 16. MEA Etanercept Share (%), by Country
  • Figure 17. North America Etanercept Share (%), by Country
  • Figure 18. Global Etanercept: by Type USD/Units (2013-2018)
  • Figure 19. Global Etanercept share by Players 2018 (%)
  • Figure 20. Global Etanercept share by Players (Top 3) 2018(%)
  • Figure 21. Global Etanercept share by Players (Top 5) 2018(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 24. Amgen (United States) Revenue: by Geography 2018
  • Figure 25. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 26. Pfizer (United States) Revenue: by Geography 2018
  • Figure 27. Takeda (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Takeda (Japan) Revenue: by Geography 2018
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2018
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2018
  • Figure 33. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Sandoz (Germany) Revenue: by Geography 2018
  • Figure 35. Celltrion (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. Celltrion (South Korea) Revenue: by Geography 2018
  • Figure 37. Dexa Medica (Indonesia) Revenue, Net Income and Gross profit
  • Figure 38. Dexa Medica (Indonesia) Revenue: by Geography 2018
  • Figure 39. Bionovis (Brazil) Revenue, Net Income and Gross profit
  • Figure 40. Bionovis (Brazil) Revenue: by Geography 2018
  • Figure 41. Momenta Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 42. Momenta Pharmaceuticals (United States) Revenue: by Geography 2018
  • Figure 43. Global Etanercept: by Type USD Million (2019-2024)
  • Figure 44. Global Etanercept: by Application USD Million (2019-2024)
  • Figure 45. South America Etanercept Share (%), by Country
  • Figure 46. Asia Pacific Etanercept Share (%), by Country
  • Figure 47. Europe Etanercept Share (%), by Country
  • Figure 48. MEA Etanercept Share (%), by Country
  • Figure 49. North America Etanercept Share (%), by Country
  • Figure 50. Global Etanercept: by Type Unit (2019-2024)
  • Figure 51. Global Etanercept: by Application Unit (2019-2024)
  • Figure 52. South America Etanercept Share (%), by Country
  • Figure 53. Asia Pacific Etanercept Share (%), by Country
  • Figure 54. Europe Etanercept Share (%), by Country
  • Figure 55. MEA Etanercept Share (%), by Country
  • Figure 56. North America Etanercept Share (%), by Country
  • Figure 57. Global Etanercept: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Amgen (United States)
  • Pfizer (United States)
  • Takeda (Japan)
  • Sanofi (France)
  • GlaxoSmithKline (United Kingdom)
  • Sandoz (Germany)
  • Celltrion (South Korea)
  • Dexa Medica (Indonesia)
  • Bionovis (Brazil)
  • Momenta Pharmaceuticals (United States)
Additional players considered in the study are as follows:
HanAll Biopharma (South Korea) , MedImmune (United States) , Tsumura (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation